advertisement

Topcon

Advances in Therapy 10

Showing records 1 to 10 | Display all abstracts in Advances in Therapy

94535 The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15
Sakata R
Advances in Therapy 2021; 38: 3760-3770
94572 Efficacy and Safety of PreserFlo MicroShunt After a Failed Trabeculectomy in Eyes with Primary Open-Angle Glaucoma: A Retrospective Study
Quaranta L
Advances in Therapy 2021; 38: 4403-4412
94535 The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15
Fujishiro T
Advances in Therapy 2021; 38: 3760-3770
94572 Efficacy and Safety of PreserFlo MicroShunt After a Failed Trabeculectomy in Eyes with Primary Open-Angle Glaucoma: A Retrospective Study
Micheletti E; Micheletti E; Carassa R
Advances in Therapy 2021; 38: 4403-4412
94535 The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15
Saito H
Advances in Therapy 2021; 38: 3760-3770
94572 Efficacy and Safety of PreserFlo MicroShunt After a Failed Trabeculectomy in Eyes with Primary Open-Angle Glaucoma: A Retrospective Study
Bruttini C
Advances in Therapy 2021; 38: 4403-4412
94535 The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15
Honjo M
Advances in Therapy 2021; 38: 3760-3770
94572 Efficacy and Safety of PreserFlo MicroShunt After a Failed Trabeculectomy in Eyes with Primary Open-Angle Glaucoma: A Retrospective Study
Fausto R
Advances in Therapy 2021; 38: 4403-4412
94535 The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15
Shirato S; Aihara M
Advances in Therapy 2021; 38: 3760-3770
94572 Efficacy and Safety of PreserFlo MicroShunt After a Failed Trabeculectomy in Eyes with Primary Open-Angle Glaucoma: A Retrospective Study
Katsanos A; Riva I
Advances in Therapy 2021; 38: 4403-4412

Issue 22-2

Change Issue


advertisement

Oculus